An early single-agent in vivo evaluation of MTX-531 focused on a determination of its therapeutic activity against high-passage HNSCC xenografts because both EGFR and PI3K have prominent roles in the progression of this disease. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.